Abstract: The present disclosure relates to methods and pharmaceutical compositions for the treatment of bone metastases. In particular, the present disclosure relates to an agent selected from the group consisting of an anti-ROB04 antibody, an anti-ROB04 aptamer, a ROB04 decoy polypeptide, an inhibitor of ROB04 expression for use in a method for preventing or treating bone meta-stases in a subject in need thereof.

Abstract: The present invention relates to methods for predicting and treating/preventing bone metastases in prostate cancer patients. In particular, the present invention relates to a method for predicting the occurrence of bone metastases in a prostate cancer patient comprising i) determining the level of expression of ERR? in a prostate tumor sample obtained from the patient, ii) comparing the level determined at step i) with a predetermined reference value and iii) concluding that there is a high risk that the patient develops bone metastases when the level determined at step i) is higher than the predetermined reference value or concluding that there is a low risk that the patient develops bone metastases when the level determined at step i) is lower than the predetermined reference value.

Abstract: The present disclosure relates to methods and pharmaceutical compositions for the treatment of bone metastases. In particular, the present disclosure relates to an agent selected from the group consisting of an anti-ROB04 antibody, an anti-ROB04 aptamer, a ROB04 decoy polypeptide, an inhibitor of ROB04 expression for use in a method for preventing or treating bone meta-stases in a subject in need thereof.

Abstract: Detection sequences of periostin having from 6 to 30 amino acids and which include all or part of peptide sequence SEQ ID No. 1, SEQ ID No. 2 or SEQ ID No. 3, or a homologous peptide sequence. Antibodies suitable for specifically recognizing minimally one of these detection sequences, including an anti-periostin antibody, are disclosed. Periostin detection and dosage processes and kits that use these antibodies are also disclosed. A periostin marker for early diagnosis, tracking and prognosis of pathologies that involve periostin, including benign osteolysis such as inflammatory diseases, including osteoarticular diseases, and malignant osteolysis, such as cancers with bone metastases, is provided.

Abstract: The present invention concerns an in vitro method for determining cancer prognosis for a patient suffering from early-stage or low-grade cancer, said method comprising measuring the expression level of ERR? in a biological sample comprising cancer cells. The invention further pertains to an in vitro method for determining bone metastases prognosis for a patient suffering from bone metastases comprising measuring the expression level of ERR?. Finally, the invention pertains to in vitro methods for selecting a patient suffering from cancer, and/or from cancer-derived metastasis, suitable to be treated with a preventive/aggressive therapy.

Abstract: The invention relates to methods and pharmaceutical compositions for the treatment of bone density related diseases. More particularly, the present invention relates to a ROBO1 modulator for use in a method for the treatment of a bone mineral density related disease in a subject. In a particular embodiment the ROBO1 modulator is selected from the group consisting of small organic molecules, antibodies, aptamers or polypeptides.

Abstract: Detection sequences of periostin having from 6 to 30 amino acids and which include all or part of peptide sequence SEQ ID No. 1, SEQ ID No. 2 or SEQ ID No. 3, or a homologous peptide sequence. Antibodies suitable for specifically recognizing minimally one of these detection sequences, including an anti-periostin antibody, are disclosed. Periostin detection and dosage processes and kits that use these antibodies are also disclosed. A periostin marker for early diagnosis, tracking and prognosis of pathologies that involve periostin, including benign osteolysis such as inflammatory diseases, including osteoarticular diseases, and malignant osteolysis, such as cancers with bone metastases, is provided.